ORCID Profile
0000-0003-0683-2951
Current Organisation
Alfred Health
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Wiley
Date: 04-05-2021
DOI: 10.1111/ANS.16906
Publisher: CSIRO Publishing
Date: 2010
DOI: 10.1071/SRB10ABS127
Abstract: The proteins that control the number of primordial follicles initially established within the ovary are largely unknown. Here we investigated the hypothesis that PUMA, a pro-apoptotic protein belonging to the Bcl-2 family, regulates germ cell death during ovarian development and thereby determines the number of primordial follicles that make up the ovarian reserve. Ovaries were obtained from embryonic day 17.5 (E17.5) and post-natal day 10 (PN10) wild-type (wt) and puma–/– mice and subjected to morphological, molecular and stereological characterisation (n = 3-6 mice/genotype/age). At E17.5, ovaries were densely populated with germ cells and early meiotic oocytes. Immunostaining for MVH and PCNA confirmed the identity of germ cells and proliferating germ cells, respectively. Pyknotic nuclei and TUNEL positive germ cells were rarely detected, suggesting that cell death was uncommon at this age. At PN10, primordial follicle assembly was complete for both genotypes, as confirmed morphologically and by immunostaining for oocyte markers GCNA and MSY2. The number of germ cells in E17.5 wt and puma–/– ovaries was comparable (p=0.81, See Table 1). However, PN10 puma–/– ovaries contained significantly more primordial follicles than wt ovaries (P 0.001, See Table 1), revealing an over-endowment of primordial follicles in the absence of PUMA. These data show that PUMA regulates the developmentally programmed death of germ cells between E17.5 and PN10 in the mouse and thereby determines the number of primordial follicles that make up the initial ovarian reserve. This work was supported by the NHMRC (Program Grants #494802 and #257502, Fellowships JKF (#441101), KJH (#494836), CLS (#406675), AS (#461299)) the Leukemia and Lymphoma Society (New York SCOR grant#7015), the National Cancer Institute (NIH, US CA80188 and CA43540) and Victorian Government Infrastructure Funds.
Publisher: Elsevier BV
Date: 04-2017
Publisher: Wiley
Date: 11-2021
DOI: 10.1111/ANS.17334
Abstract: Assessment scales are commonly used to diagnose and treat alcohol withdrawal syndrome (AWS) in acute hospitals, although they have only been validated for use in detoxification facilities. There is a significant overlap between the symptoms and signs of AWS and other clinical presentations, including systemic inflammatory response syndrome (SIRS) and the physiological response to surgery. This may lead to both over‐diagnosis and inappropriate treatment of AWS. This study sought to determine the false‐positive rate for the commonly used Clinical Institute Withdrawal Assessment for Alcohol–Revised (CIWA‐Ar) among post‐operative patients. This was a prospective study of patients undergoing major abdominal surgery at University Hospital Geelong. Patients were recruited who were NOT at risk of alcohol dependency (using the World Health Organisation Alcohol Use Disorders Identification Test). Patients were assessed for AWS using the CIWA‐Ar day one post‐operatively with a false positive measured as a CIWA‐Ar 7. A total of 67 patients were included in the study. There were 31 (46%) men and 36 women. Their median age was 52 years (range 27–85). Thirty‐six (52%) of patients underwent elective procedures, and 32 were emergencies. Twelve of the 67 patients (18%) had CIWA‐Ar scores seven. In the early post‐operative period, the CIWA‐Ar tool over‐diagnoses AWS in 18% of patients. These false‐positives could lead to delayed treatment of serious underlying conditions. We call for caution in the use of alcohol withdrawal scales in the acute hospital setting.
Location: Australia
No related grants have been discovered for Frederick Hamish Morgan.